Altimmune to Announce First Quarter 2021 Financial Results on May 17, 2021

GAITHERSBURG, Md., May 11, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2021 financial results on Monday, May 17, 2021.

Altimmune management will host a conference call for investors beginning at 8:30 am E.T. to discuss the first quarter 2021 financial results and provide a business update.   

Conference Call Information:

Date: Monday, May 17, 2021
Time:8:30 am Eastern Time
Domestic Dial-in:877-423-9813
International Dial-in: 201-689-8573
Conference ID:13719206

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Investor & Media Contacts:

Will Brown  Stacey Jurchison
Chief Financial Officer Sr. Dir, Investor Relations
Phone: 240-654-1450 Phone : 410-474-8200 

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.